Staff Reports
The election of Donald Trump as president—and his announcement that Robert F. Kennedy Jr. will play a key role in his administration—is nothing short of a nightmare scenario for Big Pharma. Kennedy has spent years taking on the pharmaceutical industry and the corrupt systems that keep it thriving. Now, with a powerful new position potentially over the FDA or CDC, Kennedy is primed to shake up the industry like no one before.
For decades, the relationship between Big Pharma and government health agencies has been a quiet but well-oiled machine. The FDA, the CDC, and even the National Institutes of Health have been in and out of deals and partnerships with top pharmaceutical companies, often working in tandem on drug approvals, vaccine rollouts, and public health policy. This “revolving door” between regulators and the industry is no secret, and Kennedy has been a vocal critic of the setup. From executives who move from Big Pharma to high positions in regulatory agencies, to government officials who walk right into industry jobs, the pattern is troubling. It puts profits over public health and leaves American citizens as collateral damage.
Kennedy’s stance is clear: public health should be based on safety, efficacy, and real scientific integrity—not on corporate profits. His criticism isn’t just talk. Kennedy has put years into investigating conflicts of interest, exposing industry-funded “science,” and fighting for transparency, especially when it comes to issues that impact families, like vaccine safety and environmental toxins. He has questioned the industry’s unchallenged power, particularly around the influence it exerts over lawmakers and regulators who are supposed to hold it accountable. In an industry that routinely makes billions off taxpayer-funded research, the mere thought of Kennedy in a leadership position is shaking Big Pharma to its core.
One key target for Kennedy is the Prescription Drug User Fee Act, which has enabled the pharmaceutical industry to provide substantial funding to the FDA—often in exchange for fast-tracked approvals and favorable reviews. This funding structure raises significant ethical questions: Can an agency charged with protecting public health really function in the public’s interest when it’s financially tied to the industry it regulates? Kennedy has argued that these cozy relationships between government health officials and drug companies compromise the very mission of the FDA, turning it into a rubber stamp for pharmaceutical profits instead of a watchdog for the people.
With his “Make America Healthy Again” mission, Kennedy has vowed to confront not just drugs and vaccines but the broader environmental and lifestyle factors that contribute to America’s skyrocketing rates of chronic disease. From banning toxic pesticides and food additives to addressing industrial pollution, his agenda reflects a commitment to tackling the root causes of health issues—not just slapping Band-Aids on symptoms. Under Kennedy’s watch, Americans can expect a laser focus on transparency, true scientific inquiry, and policies aimed at protecting our families from preventable health risks.
It’s no wonder Big Pharma is panicking. Kennedy is a thorn in their side who’s known for exposing ugly truths. His approach threatens to disrupt the business models of companies that have become far too accustomed to setting their own rules. His potential leadership at the FDA or CDC isn’t about adjusting a few policies here and there; it’s about pulling back the curtain and cleaning house. In fact, Kennedy could force Big Pharma to overhaul its entire approach—putting patient welfare above their own profit margins.
Big Pharma’s apprehension here is a testament to the powerful shift that Kennedy’s leadership could bring. He is serious about accountability, and for the first time, we may see government agencies operating without the shadow of industry influence hanging over them. Finally, there’s a chance that public health could actually become about the public.
As Trump and Kennedy team up, Big Pharma will no longer have the cozy partnership with federal agencies that it once took for granted. Public health is about to get a major shake-up, and for the first time in a long time, the American people stand to benefit.
